With J-Pharma, Newton Biocapital closed its second investment in Japan !
get in touch
Fostering new solutions
for chronic diseases
What we invest in
Newton Biocapital's approach is to support promising startup projects as well as neglected or undervalued late-stage life sciences companies in the "core of Europe" and Japan. We invest in therapeutic, diagnostic, medical device, clinical nutrition and digital biotech companies that share our vision: developing solutions for the prevention and treatment of chronic diseases.our scope
By joining forces with passionate bio-entrepreneurs, we develop and implement business strategies that will lead to a strong proof of concept, demonstrating clinical potential and/or market value.
Our trans-continental approach links two important life sciences markets and allows better access to important corporate networks, larger management pools, wider scientific communities and different capital markets.our investment approach
Newton Biocapital brings together an experienced team of industry and venture capital professionals. This allows us to leverage our strategic insights to create value for both patients and investors.
Our mode-of-operation includes attention to scientific discoveries which might lead to innovative projects. Because we, for one, are focusing on ‘early-stage’ start-ups. On August 2, 2019 a delegation of Newton BioCapital was hosted by Prof. Yoshinori Ohsumi in his Cell Biology Centre of the Tokyo Institute of Technology in Yokohama. Prof. Ohsumi is the 2016-Nobel laureate for Medicine for his discoveries on cell-autophagy. His innovative work builds on earlier pioneering work of Nobel-laureate C. De Duve (1974) who identified the role of the lysosome. There is an obvious elegant mirror-situation between the roots of NBC I in W-EU and Japan, and what these 2 “giants “of physiology have contributed to our understanding of the functional constituents of a cell.meet the team